Clinical trials
Autoimmune clinical trials
Below are recruiting autoimmune clinical trials, each written for real people, not researchers. We’re tracking 346 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06235580Recruiting
Genetics and immune-brain health study
This study looks at genetic diseases that affect the immune system and the brain. It aims to better understand these conditions by comparing patients, their relatives, and healthy controls.
Paris, Île-de-France RegionAges Any age - NCT06248957Recruiting
Immune system study for people with hard-to-treat immune diseases
This study aims to understand the immune system in people who have immune problems or whose immune-related diseases are not helped by standard treatments. It may lead to better ways to diagnose and treat these conditions.
StockholmAges Any age - NCT06249438RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06272084Recruiting
Review of plasmapheresis treatments (TPE) using multiFiltratePRO
This study looks back at the medical records of people who had plasmapheresis (TPE) treatment to learn more about how it works. If you had this treatment between 2019 and 2023, researchers may use your data.
Aschaffenburg, BavariaAges 18 years+ - NCT06278337Recruiting
Moesin-associated immunodeficiency study
This study looks at a rare immune system condition caused by changes in the MOESIN gene. It aims to better understand the condition and may help develop future treatments.
Bethesda, MarylandAges 4–80 - NCT06283316Recruiting
A registry for alopecia areata treatments
This trial is a registry that collects information from people with alopecia areata who are starting or using body-wide treatments. It helps doctors learn more about how these treatments work in real life.
RotterdamAges 16 years+ - NCT06308978RecruitingPhase 1
Study of FT819 for B-cell autoimmune diseases
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
Beverly Hills, CaliforniaAges 12–70 - NCT06316076RecruitingPhase 1
CD19 CAR-T cell therapy for autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-T cells targeting CD19) for people with autoimmune diseases that haven't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
ShanghaiAges 18–65 - NCT06316791RecruitingEarly Phase 1
CNCT19 CAR-T therapy for refractory autoimmune diseases
This early-phase study tests a new CAR-T cell therapy (CNCT19) for people with certain autoimmune diseases that have not responded to standard treatments. It targets a protein called CD19 on immune cells to help reset the immune system and reduce disease activity.
Zhengzhou, HenanAges 18–70 - NCT06321588Recruiting
Autoimmune dementia: predicting antibodies in new cognitive decline
This study looks for certain antibodies that might be causing your new memory or thinking problems. It aims to find patterns that could help diagnose autoimmune dementia earlier.
Bologna, BolognaAges 40–90 - NCT06339957Recruiting
Rheumatology diet study for arthritis and related conditions
This study looks at how diet affects people with different types of arthritis and related autoimmune conditions. If you are a UCF Health patient between 18 and 65, you may be able to help researchers learn more about which foods help or worsen symptoms.
Orlando, FloridaAges 18–65 - NCT06347718RecruitingPhase 1/Phase 2
Car-T cells for autoimmune disease
This study tests a type of immunotherapy called CAR-T cells for people with certain autoimmune diseases like lupus, scleroderma, or myositis. It aims to see if this treatment can help when standard medicines haven't worked well enough.
Erlangen, BavariaAges 18 years+ - NCT06350110RecruitingPhase 1/Phase 2
CAR T cells for lupus
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
Beijing, Beijing MunicipalityAges 18–90 - NCT06379646Recruiting
YTS109 cell therapy for autoimmune disease
This study tests a new cell therapy (YTS109) for people with autoimmune diseases like lupus or Sjogren's syndrome that have not improved or keep coming back after standard treatments. It aims to see if the treatment can help control the disease.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06382675Recruiting
Testing a new plasma filter for blood cleaning treatment
This trial tests a new plasma filter, PX2, used in a procedure called therapeutic plasma exchange (TPE) to clean harmful substances from your blood. It’s for people who already need TPE and can safely use a blood thinner during the treatment.
Aschaffenburg, BavariaAges 18 years+ - NCT06388161Recruiting
Autoantibody study in new focal seizures
This research study looks for specific immune system markers (autoantibodies) in the blood and spinal fluid of people who have recently started having focal seizures (seizures that start in one part of the brain) with no known cause. Finding these markers could help doctors understand why the seizures started.
Hangzhou, ZhejiangAges 14–100 - NCT06405373Recruiting
Coping skills program for type 1 diabetes distress
This study tests a program to help adults with type 1 diabetes who feel stressed or overwhelmed by their condition. You'll join virtual group sessions to learn coping skills and track how your distress changes over time.
Chapel Hill, North CarolinaAges 30 years+ - NCT06417502Recruiting
China pediatric rheumatic disease registry study
This study collects information from children with rheumatic and immune system diseases in China to better understand these conditions. By participating, you help researchers learn more about how to diagnose and treat these diseases.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT06426316Recruiting
Immune cells and migraines study
This study looks at how certain immune cells and inflammatory chemicals relate to migraines. If you have migraines or an autoimmune condition (like lupus, rheumatoid arthritis, or Crohn's disease), you may be able to participate. The goal is to understand what causes migraines.
Clermont-Ferrand, AURAAges 18–50 - NCT06452654RecruitingPhase 4
Vaccine to prevent type 1 diabetes in high-risk babies
This study tests whether a vaccine given to very young babies (3–4 months old) can prevent type 1 diabetes. It is designed for babies who have a high genetic risk and a family history of the disease.
ViennaAges 3 months–4 months - NCT06465147RecruitingPhase 1
Cell therapy for hard-to-treat lupus (REACT-01)
This trial tests a new type of cell therapy (CAR T-cells) to see if it can stop the immune system from attacking the body in severe lupus. It’s for people ages 2–30 whose lupus is not controlled by other treatments and who are willing to be treated at Seattle Children’s Hospital.
Seattle, WashingtonAges 2–30 - NCT06469788Recruiting
COVID-19 vaccine navigation for rheumatology patients
This study looks at helping Black and Latinx adults with autoimmune rheumatic diseases get the updated COVID-19 vaccine. It offers information and support (like testimonials and navigation help) to see what works best.
Birmingham, AlabamaAges 18 years+ - NCT06519162Recruiting
Liver-gut link study for liver disease patients and their families
This study looks at how gut bacteria differ in people with specific liver diseases and their household contacts. It may help researchers understand the connection between the liver and gut.
Daejeon, Jung-guAges 19 years+ - NCT06557265RecruitingPhase 1/Phase 2
NKX019 for lupus kidney disease or membranous nephropathy
This trial tests an experimental cell therapy called NKX019 for people with active lupus nephritis (a type of kidney inflammation from lupus) or primary membranous nephropathy (another kidney condition) that hasn't gotten better after standard treatments. It may help if you have tried at least two treatments for lupus kidney disease or one for membranous nephropathy and still have active kidney disease.
Little Rock, ArkansasAges 18–75
Hear when a new Autoimmune trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autoimmune?
- Yes. Clin2 currently lists 346 recruiting autoimmune studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autoimmune trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autoimmune trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.